Story perspectives

GLP-1 Therapies: Weight Loss and Inflammation Benefits Unveiled

11/6/2025

45 6

Summary

Story summary

Glucagon-like peptide-1 (GLP-1)-based therapies, including semaglutide and liraglutide, lower glucose, promote weight loss, and show anti-inflammatory effects.
Clinical and preclinical studies show these drugs reduce systemic inflammation by lowering C-reactive protein and pro-inflammatory cytokines.
Benefits in type 2 diabetes and obesity are established.
More research is needed to understand mechanisms and potential effects on neurodegenerative diseases and arthritis.
Current evidence shows no increased infection or cancer risks.

1 of 1

Story summary

Glucagon-like peptide-1 (GLP-1)-based therapies, including semaglutide and liraglutide, lower glucose, promote weight loss, and show anti-inflammatory effects.
Clinical and preclinical studies show these drugs reduce systemic inflammation by lowering C-reactive protein and pro-inflammatory cytokines.
Benefits in type 2 diabetes and obesity are established.
More research is needed to understand mechanisms and potential effects on neurodegenerative diseases and arthritis.
Current evidence shows no increased infection or cancer risks.